Intellia Therapeutics (NTLA) Gains from Sales and Divestitures (2016 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Gains from Sales and Divestitures data on file, last reported at $1.5 million in Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $1.5 million, up 0.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 0.53% YoY), and the FY2025 annual result was $2.1 million, up 44.87% from the prior year.
• Gains from Sales and Divestitures fell to $1.5 million in Q1 2026 per NTLA's latest filing, from $2.1 million in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $2.1 million in Q4 2025 and troughed at $54666.0 in Q1 2022.
• A 5-year average of $946269.9 and a median of $1.0 million in 2024 frame the typical range for Gains from Sales and Divestitures.
• The sharpest annual moves came in 2023 and 2026: Gains from Sales and Divestitures jumped 550.69% in 2023, then gained 0.53% in 2026.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $147674.0 in 2022, then soared by 358.48% to $677055.0 in 2023, then surged by 111.75% to $1.4 million in 2024, then jumped by 44.87% to $2.1 million in 2025, then dropped by 26.91% to $1.5 million in 2026.
• Business Quant data shows NTLA's Gains from Sales and Divestitures at $1.5 million in Q1 2026, $2.1 million in Q4 2025, and $1.8 million in Q3 2025.